Literature DB >> 11514949

Comparative disposition of ricobendazole enantiomers after intravenous and subcutaneous administration of a racemic formulation to calves.

C Cristòfol1, G Virkel, L Alvarez, M Arboix, C E Lanusse.   

Abstract

The enantioselective disposition kinetics of the benzimidazole anthelmintic, ricobendazole (RBZ), have been characterized after its intravenous (iv) and subcutaneous (sc) administration as a racemic formulation to cattle. The (+) and (-) RBZ enantiomeric forms were recovered in plasma after iv and sc administration of the racemic RBZ formulation, using a chiral phase based HPLC method. A biexponential plasma concentration versus time curve was observed for both RBZ enantiomers following the iv treatment. Total body clearance was higher for (-) RBZ (150.4 mL/h. kg) compared with that obtained for the (+) RBZ antipode (78.1 mL/h. kg). The elimination half-life of the (-) RBZ enantiomer was shorter (T1/2beta: 2.67 h) compared with the (+) enantiomer (T1/2beta: 5.41 h). The plasma availability (expressed as AUC) was significantly higher for (+) RBZ compared with that obtained for the (-) antipode following both treatments. The enantiomeric ratio in plasma at T(0) was close to unity (50% of each enantiomer); the analysis of the concentration ratios (+) RBZ/(-) RBZ, demonstrated an increase in the proportion of (+) RBZ during the time course of the kinetics after both iv and sc treatments. The results presented herein show the enantioselective disposition kinetics of RBZ in cattle and are a further contribution to the understanding of the kinetic behaviour of these sulphoxide-containing benzimidazole anthelmintics in ruminants. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11514949     DOI: 10.1002/bdd.246

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  3 in total

1.  Enantiomerical pharmacokinetic prevalence of (+) albendazole sulphoxide in Trichinella spiralis muscle larvae.

Authors:  Juan José García-Rodríguez; María Carmen Del Vegas-Sánchez; Juan José Torrado-Durán; Francisco Bolás-Fernández
Journal:  Parasitol Res       Date:  2011-08-16       Impact factor: 2.289

2.  Aspects of the pharmacokinetics of albendazole sulphoxide in sheep.

Authors:  A Goudah
Journal:  Vet Res Commun       Date:  2003-10       Impact factor: 2.459

3.  Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats.

Authors:  Dilek Aksit; Hande Sultan Yalinkilinc; Selim Sekkin; Murat Boyacioğlu; Veli Yilgor Cirak; Erol Ayaz; Cengiz Gokbulut
Journal:  BMC Vet Res       Date:  2015-05-27       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.